The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

Researchers identified a direct connection between cancer-related inflammation and the loss of motivation characteristic of advanced cancer. In a mouse study, they describe a brain pathway that starts ...

Eldiara, 22, received news of a very rare form of the disease in 2021 and has since been treated with chemotherapy and had to ...

Eldiara was diagnosed with stage 3 synovial sarcoma, a rare type of soft tissue cancer, when she was just 19 years old – and ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.